Paul Silva - Vertex Pharmaceuticals Senior Vice President Corporate Controller

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 35px;;'>VRT</div>
VRTX -- USA Stock  

Earning Report: February 4, 2020  

  President
Mr. Paul M. Silva is Senior Vice President, Controller of the company, and he is no longer as Interim Chief Financial Officer, Effective April 10, 2019. Mr. Silva is our Senior Vice President and Corporationrationrate Controller, a position he has held since April 2011. Mr. Silva joined us in August 2007 as Senior Director, Accounting Operations and was our Vice President and Corporationrationrate Controller from September 2008 through April 2011. Prior to joining us, he was the Vice President, Internal Reporting at Iron Mountain Incorporated from July 2006 until August 2007 and a consultant to Iron Mountains financing department from April 2005 until July 2006. He was the Finance Director of the Bioscience Technologies Division of Thermo Electron Corporationrationration from 2002 to April 2005
Age: 51  President Since 2019      
617 341-6100  www.vrtx.com
Silva holds a B.S. in accounting from Assumption College.

Paul Silva Latest Insider Activity

Management Efficiency

The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Saumen ChakrabortyDr Reddys Laboratories Ltd
2018
Louis YuPerrigo Company Plc
2013
Marc CouckePerrigo Company Plc
N/A
Daniel PlewRegeneron Pharmaceuticals
2016
Glenn DavidZoetis
2016
Andrew FentonZoetis
2018
Stefan WeiskopfZoetis
2013
Joyce LeeZoetis
2012
Joseph LaRosaRegeneron Pharmaceuticals
2019
Thomas FarringtonPerrigo Company Plc
2015
Alejandro BernalZoetis
2015
Umang VohraDr Reddys Laboratories Ltd
2013
Svend AndersenPerrigo Company Plc
2017
Paul WeningerPerrigo Company Plc
2015
Ganadhish KamatDr Reddys Laboratories Ltd
2016
Michael StewartPerrigo Company Plc
2004
Jay MarkowitzRegeneron Pharmaceuticals
2017
Christopher FenimoreRegeneron Pharmaceuticals
2017
George YancopoulosRegeneron Pharmaceuticals
2016
Samiran DasDr Reddys Laboratories Ltd
2016
Douglas McCorkleRegeneron Pharmaceuticals
2007

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run Balance Of Power Now

   

Balance Of Power

Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
All  Next Launch Module

Also Currentnly Active

Purchased over 30 shares of
few hours ago
Traded for 80.1
Purchased over 300 shares of
few hours ago
Traded for 9.16
Purchased over 50 shares of
few hours ago
Traded for 58.39
Also please take a look at World Market Map. Please also try Chance of Distress module to get analysis of equity chance of financial distress in the next 2 years.